• 01.11.2019 – 10:16

  REstore

  RESTORE 1st Advanced Therapies Science Meeting

  Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...

• 28.10.2019 – 10:10

  Top Aces Inc

  Top Aces Receives Notice of IDIQ Award

  Mesa, Arizona (ots/PRNewswire) - Advanced adversary air training leader ideally positioned to be key provider - Top Aces Corp. is pleased to announce that it has been selected as a winner under the U.S. Air Force Combat Air Force Contracted Air Support contract. This contract provides a vehicle through which Top Aces can offer it's highly advanced adversary air capabilities and compete for individual tenders at twelve ...

• 05.09.2019 – 09:00

  Yanfeng Automotive Interiors

  

  Yanfeng pioneers Hygiene Technologies for Shared Mobility in Smart Cabins / Advanced, health-focused smart technologies for a premium user experience

• 14.02.2019 – 09:00

  Debiopharm International SA

  

  Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion

• 30.01.2019 – 08:12

  ForaCare Suisse AG

  

  2

  ForaCare Suisse AG forms service-oriented partnership with B. Braun

• 21.12.2018 – 20:02

  Merck KGaA

  Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...